Session

IBD (Posters)

COLONIC ORGANOIDS FOR THE INVESTIGATION OF CLINICAL RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR AGENTS IN PATIENTS WITH ULCERATIVE COLITIS
COLONIC ORGANOIDS FOR THE INVESTIGATION OF CLINICAL RESPONSIVENESS TO ANTI-TUMOR NECROSIS FACTOR AGENTS IN PATIENTS WITH ULCERATIVE COLITIS

NOVEL APPROACH TO BIND AND SPECIFICALLY DETECT FIMH-EXPRESSING E. COLI USING HEPTYLMANNOSE-FUNCTIONALIZED CELLULOSE IN THE CONTEXT OF CROHN'S DISEASE
NOVEL APPROACH TO BIND AND SPECIFICALLY DETECT FIMH-EXPRESSING E. COLI USING HEPTYLMANNOSE-FUNCTIONALIZED CELLULOSE IN THE CONTEXT OF CROHN'S DISEASE

BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL
BODY MASS INDEX DOES NOT IMPACT CLINICAL EFFICACY OF USTEKINUMAB IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF THE IM-UNITI TRIAL

SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE
SYSTEMATIC REVIEW AND META-ANALYSIS: SAFETY OF VEDOLIZUMAB DURING PREGNANCY IN FEMALE PATIENTS WITH INFLAMMATORY BOWEL DISEASE

SWITCHING FROM ORIGINATOR ADALIMUMAB (HUMIRA®) TO BIOSIMILAR (HULIO®) IN AN IBD POPULATION
SWITCHING FROM ORIGINATOR ADALIMUMAB (HUMIRA®) TO BIOSIMILAR (HULIO®) IN AN IBD POPULATION

EFFICACY AND SAFETY OF USTEKINUMAB IN CROHN'S DISEASE: A REAL-WORLD STUDY FROM THE UNITED KINGDOM
EFFICACY AND SAFETY OF USTEKINUMAB IN CROHN'S DISEASE: A REAL-WORLD STUDY FROM THE UNITED KINGDOM

COMPARISON STUDY BETWEEN PROMONITOR QUICK IFX AND QUANTUM BLUE® INFLIXIMAB FOR THE QUANTIFICATION OF INFLIXIMAB LEVELS
COMPARISON STUDY BETWEEN PROMONITOR QUICK IFX AND QUANTUM BLUE® INFLIXIMAB FOR THE QUANTIFICATION OF INFLIXIMAB LEVELS

FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY
FECAL CALPROTECTIN AND DRUG LEVELS AT WEEK 14 PREDICT LONG-TERM RESPONSE OF VEDOLIZUMAB IN PAEDIATRIC INFLAMMATORY BOWEL DISEASES: A REPORT FROM THE PROSPECTIVE, MULTI-CENTRE VEDOKIDS STUDY

LOCAL APPLICATION OF AUTOLOGOUS PLATELET-RICH PLASMA IS SAFE AND EFFECTIVE IN TREATMENT OF COMPLEX CROHN`S PERIANAL FISTULAE - RESULTS FROM SINGLE CENTER PILOT STUDY
LOCAL APPLICATION OF AUTOLOGOUS PLATELET-RICH PLASMA IS SAFE AND EFFECTIVE IN TREATMENT OF COMPLEX CROHN`S PERIANAL FISTULAE - RESULTS FROM SINGLE CENTER PILOT STUDY

COMBINATION THERAPY IN IBD PATIENTS: DO WE NEED TO MAXIMIZE THE DOSE OF AZATHIOPRINE?
COMBINATION THERAPY IN IBD PATIENTS: DO WE NEED TO MAXIMIZE THE DOSE OF AZATHIOPRINE?

INFLAMMATORY BOWEL DISEASE AND CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERISTICS IN A MULTIDISCIPLINARY APPROACH
INFLAMMATORY BOWEL DISEASE AND CONCOMITANT ENDOMETRIOSIS: FREQUENCY AND CHARACTERISTICS IN A MULTIDISCIPLINARY APPROACH

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

QUALITY OF LIFE, FECAL CALPROTECTIN AND ENDOSCOPIC DISEASE ACTIVITY: A STUDY OF CORRELATION IN INFLAMMATORY BOWEL DISEASE
QUALITY OF LIFE, FECAL CALPROTECTIN AND ENDOSCOPIC DISEASE ACTIVITY: A STUDY OF CORRELATION IN INFLAMMATORY BOWEL DISEASE

THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH OPHTHALMIC DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH OPHTHALMIC DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH DERMATOLOGICAL DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE
THE RISK OF LATER DEVELOPING INFLAMMATORY BOWEL DISEASE IN SUBJECTS WITH DERMATOLOGICAL DISORDERS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
HUMANISTIC BURDEN AND IMPACT OF THE DISEASE IN MODERATE TO SEVERE PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC): FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)
CORTICOSTEROID USE AND THE ASSOCIATED IMPACT ON PATIENTS WITH CROHN'S DISEASE (CD) AND ULCERATIVE COLITIS (UC) IN THE US, FRANCE, GERMANY, ITALY, SPAIN, AND UK (EU5)

ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB
ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY
EFFECTS OF OZANIMOD ON CIRCULATING LYMPHOCYTES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: FLOW CYTOMETRY RESULTS FROM THE STEPSTONE PHASE 2 STUDY

Item 21 - 40 / 558
1
2
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28